Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Kuboki

Showing results (121-130 of 126) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 126 results.
ESMO Gastrointestinal Oncology|February 6, 2026
Temporal dynamics of CLDN18.2 expression following zolbetuximab treatment in advanced gastric cancerK Yamamoto, I Nakayama, N Sakamoto, et al.
ESMO Open|October 24, 2025
Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancersK Muro, K Chin, S B Maron, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Clinical implementation of simultaneous multiple biomarkers testing for metastatic or recurrent gastroesophageal adenocarcinoma: a single-institutional experienceU Okazaki, I Nakayama, N Sakamoto, et al.
ESMO Open|June 13, 2025
Clinical characterization of FGFR2b expression in patients with advanced gastric or gastroesophageal junction adenocarcinomaS Sato, S L Rhodes, Y Aoki, et al.
ESMO Gastrointestinal Oncology|April 17, 2026
Impact of claudin 18.2 expression on the efficacy of trastuzumab deruxtecan in patients with HER2-positive gastric or gastroesophageal junction cancerD Okemoto, I Nakayama, A Jubashi, et al.
ESMO Open|October 1, 2025
Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancerK Yamamoto, Y Owaki, I Nakayama, et al.
Pageof 13

Showing results (121-130 of 126) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 126 results.
ESMO Gastrointestinal Oncology|February 6, 2026
Temporal dynamics of CLDN18.2 expression following zolbetuximab treatment in advanced gastric cancerK Yamamoto, I Nakayama, N Sakamoto, et al.
ESMO Open|October 24, 2025
Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancersK Muro, K Chin, S B Maron, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Clinical implementation of simultaneous multiple biomarkers testing for metastatic or recurrent gastroesophageal adenocarcinoma: a single-institutional experienceU Okazaki, I Nakayama, N Sakamoto, et al.
ESMO Open|June 13, 2025
Clinical characterization of FGFR2b expression in patients with advanced gastric or gastroesophageal junction adenocarcinomaS Sato, S L Rhodes, Y Aoki, et al.
ESMO Gastrointestinal Oncology|April 17, 2026
Impact of claudin 18.2 expression on the efficacy of trastuzumab deruxtecan in patients with HER2-positive gastric or gastroesophageal junction cancerD Okemoto, I Nakayama, A Jubashi, et al.
ESMO Open|October 1, 2025
Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancerK Yamamoto, Y Owaki, I Nakayama, et al.
Pageof 13